<DOC>
	<DOCNO>NCT00331851</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe South America . This trial design show effect treatment liraglutide add exist glimepiride metformin combination therapy compare effect insulin glargine add combination therapy glimepiride metformin .</brief_summary>
	<brief_title>Effect Liraglutide Blood Glucose Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Treatment oral antidiabetic drug least 3 month HbA1c : 7.510.0 % ( incl . ) subject OAD monotherapy . 7.010.0 % ( incl . ) subject OAD combination therapy . Body Mass Index ( BMI ) less equal 45 kg/m2 Treatment insulin within last 3 month Treatment drug could interfere glucose level Any serious medical condition Females pregnant , intention become pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>